Protagenic Therapeutics, Inc.new (PTIX) stock
PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Protagenic Therapeutics, Inc.new operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Protagenic Therapeutics, Inc.new's operating income for the twelve months ending Dec 31, 2024 was -$5.70M. For fiscal 2024 it was -$5.70M. The highest annual figure on record is -$2.09M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$5.70M | – |
| FY2023 | Dec 31, 2023 | -$4.53M | – |
| FY2022 | Dec 31, 2022 | -$3.56M | – |
| FY2021 | Dec 31, 2021 | -$4.14M | – |
| FY2020 | Dec 31, 2020 | -$2.55M | – |
| FY2019 | Dec 31, 2019 | -$2.09M | – |
| FY2018 | Dec 31, 2018 | -$2.31M | – |
| FY2017 | Dec 31, 2017 | -$2.37M | – |
| FY2016 | Dec 31, 2016 | -$2.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ1 2026 | Jun 30, 2026 | -$961.25K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$401.40K | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$355.37K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$321.83K | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$1.74M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$1.21M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$1.43M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.14M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$739.29K | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$655.78K | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$924.06K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$636.67K | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$1.34M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$861.22K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$764.17K | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$1.31M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$1.21M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$536.88K | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$1.09M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$488.94K | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$520.74K | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$737.23K | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$189.62K | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$505.26K | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$654.02K | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$524.25K | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$498.07K | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$685.13K | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$606.68K | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$708.78K | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$527.03K | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$471.59K | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$657.92K | – |
| Q4 FY2016CQ4 2016 | Dec 31, 2016 | -$556.28K | – |
| Q3 FY2016CQ3 2016 | Sep 30, 2016 | -$454.83K | – |
| Q2 FY2016CQ2 2016 | Jun 30, 2016 | -$496.66K | – |
| Q1 FY2016CQ1 2016 | Mar 31, 2016 | -$725.74K | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | -$398.00K | – |
| Q2 FY2014CQ4 2013 | Dec 31, 2013 | -$242.00K | – |
See a number that looks wrong?